The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need ...

Nina Balanchivadze, MD, FACP, discusses how inclusive research begins at the community level by addressing barriers to trial ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Patients with post-traumatic stress disorder (PTSD) often struggle to forget traumatic memories, even long after the danger ...

Key Points - GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates. GAAP loss per share ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data ...